During a live event, Taewoong Choi, MD, discussed the potential use of quadruplet in transplant-ineligible multiple myeloma ...

Hypogammaglobulinemia either as an adverse reaction or laboratory IgG level below 500mg/dl, after infusion occurred in 94% (267/285) of patients treated. ... ABOUT MULTIPLE MYELOMA.

Over half of these pipelines target non-solid tumors (such as multiple myeloma and various types of lymphoma ... TCE bispecific antibodies offer substantial advantages over standard IgG monoclonal ...

The good news, I guess, is that we have very many different treatment options for relapse refractory multiple myeloma, and some of that is considered in the background of what we do for patients with ...

Financial, family, and logistical challenges often lead patients to choose ongoing therapies over stem cell transplantation, ...

I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened ...

Explore the innovative subcutaneous delivery of isatuximab for multiple myeloma, enhancing patient experience and treatment ...

On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for ...

A total of 97 patients with relapsed or refractory multiple myeloma (RRMM), each previously treated with at least three lines of therapy and nearly all triple-class refractory, received a single ...

Multiple myeloma — cancer of the white blood cells known as plasma cells — can cause a vast spectrum of symptoms as it progresses. But multiple myeloma often has no outward signs in its early ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...